Cellectis SA (CLLS) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 EPS of -$0.26, reflecting ongoing R&D investments in gene-editing therapies.
• Consensus revenue estimate around €8.71 million, down 19.5% year-over-year amid clinical trial focus.
• Cash position of $211 million as of year-end 2025 supports runway into H2 2027, key for investor confidence.
• Key metrics to monitor: progress in BALLI-01 and NATHALI-01 trials, partnership milestones.
• Stock trades at elevated volatility; historical reactions show sensitivity to clinical updates.
• Full-year 2026 revenue consensus at €51.58 million, implying moderated growth trajectory.

Earnings Context and Why It Matters

Cellectis S.A. (CLLS), a clinical-stage biotech pioneering gene-editing for cell and gene therapies, operates in the high-stakes immuno-oncology space. Q1 2026 earnings, expected late April, will shed light on cash burn post the robust $211 million position at 2025 year-end. With pivotal trials like BALLI-01 for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) advancing, investors seek validation of clinical momentum and partnership revenues from Servier, Allogene, and AstraZeneca. Amid biotech sector funding challenges, this report matters for gauging runway extension and pipeline de-risking, influencing stock sentiment in a volatile market.

Earnings Expectations

Consensus calls for Q1 2026 (period ending March 31, 2026) EPS of -$0.26, with a range from -$0.20 to -$0.34, per analyst averages. Revenue estimates hover at €8.71 million (about $9.3 million), down from €10.82 million last year, driven by collaboration and licensing income rather than product sales in this pre-commercial phase. Investors watch R&D expenses tied to TALEN^® platform advancements and manufacturing scale-up.

Past performance shows mixed beats: Q4 2025 EPS missed at -$0.26 vs. -$0.20 expected, but revenue topped forecasts; Q3 surprised positively with $0.01 vs. -$0.23. Stock historically swings 10-20% post-earnings, amplified by clinical news. Guidance on cash usage and trial enrollment will be pivotal, alongside updates on low-dose IL-2 cohorts.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to uncover potential plays in biotech like CLLS.

Market Reaction and Investor Sentiment

Heading into Q1 earnings (est. Apr 30-May 18), sentiment is cautious yet optimistic on clinical catalysts. Shares have stabilized post-Q4 miss (revenue beat but EPS shortfall), trading around $4 amid broader biotech recovery. Risks include higher-than-expected opex (operating expenses) or trial delays; upsides from positive interim data like cema-cel futility analysis in April. Implied volatility suggests ±15% move, with focus on cash preservation.

Forward Outlook and Key Factors to Monitor

Post-Q1, watch cash runway updates; $211 million supports operations into H2 2027, but milestone timing from partners like Allogene/Servier could extend it further.

Clinical milestones dominate: BALLI-01 Phase 2 interim in Q4 2026, NATHALI-01 full Phase 1 data same period, plus IL-2 cohort initiation. Cema-cel (ALPHA3) interim futility analysis in April 2026 could validate allogeneic CAR-T (chimeric antigen receptor T-cell) edge over autologous therapies.

Industry dynamics include gene-editing competition (e.g., CRISPR peers) and manufacturing costs. Monitor R&D spend trends, as margins pressure persists pre-revenue. Partnership progress with AstraZeneca under Joint Research Agreement signals potential upsides. Balanced view: pipeline promise vs. dilution risks if cash dips faster.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations